Unknown cellular targets

The term 'Unknown cellular targets' is a placeholder used in pharmacology to indicate that the specific molecular entity responsible for a drug's effect has not been identified (Moffat et al., 2017, Nature Reviews Drug Discovery). This situation frequently arises from phenotypic screening, where small molecules are selected based on their ability to produce a desired biological outcome in cells or organisms rather than binding to a pre-selected protein (Swinney & Anthony, 2011, Nature Reviews Drug Discovery). Although the compound may show therapeutic potential, the absence of a defined target complicates the understanding of its biochemical pathway and mechanism of action (Ziegler et al., 2013, Cell Chemical Biology). Target deconvolution techniques, such as chemical proteomics or genetic interaction mapping, are typically employed to transition from an unknown target to a specific molecular interactor (Haura, 2011, Clinical Cancer Research). Knowing the target is vital for assessing the risk of off-target toxicity and for the rational design of more potent analogs (Terstappen et al., 2007, Nature Reviews Drug Discovery). In clinical development, drugs with unknown targets face higher regulatory scrutiny regarding their safety and long-term effects. Therefore, this designation represents a significant gap in mechanistic knowledge that researchers strive to fill to ensure drug efficacy and safety.

The mechanism of action is undefined because the specific molecular interactor has not been identified.